Marker Therapeutics (MRKR) Share-based Compensation (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Share-based Compensation of $800000.0 for Q1 2026, up 111.0% year-over-year from $379144.0 in Q1 2025, and up 619.87% quarter-over-quarter from $111131.0 in Q4 2025.
Marker Therapeutics (MRKR) Share-based Compensation (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Share-based Compensation for 17 consecutive years, with $800000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 111.0% year-over-year to $800000.0; the TTM figure through Mar 2026 stood at $800000.0 (up 46.63% YoY), while the FY2025 annual figure was $900000.0, up 266.06% from the prior year.
- Share-based Compensation climbed to $800000.0 in Q1 2026 per MRKR's latest filing, from $111131.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.6 million in Q1 2022 and bottomed at -$581731.0 in Q4 2023.
- Historically, Share-based Compensation has averaged $458074.7 across 5 years, with a median of $175000.0 in 2023.
- Annual changes were most pronounced in 2023 — Share-based Compensation slumped 181.13% — and 2025, when it jumped 379.93%.
- Marker Therapeutics' Share-based Compensation stood at $717000.0 in 2022, then plunged by 181.13% to -$581731.0 in 2023, then surged by 108.69% to $50544.0 in 2024, then surged by 119.87% to $111131.0 in 2025, then soared by 619.87% to $800000.0 in 2026.
- Business Quant data shows MRKR's Share-based Compensation at $800000.0 in Q1 2026, $111131.0 in Q4 2025, and $33279.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | - |
| 10 | Marker Therapeutics | 25.07 Mn | 13.14 Mn | - | 600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 111,131.00 |
| Dec 31, 2025 | 111,131.00 |
| Sep 30, 2025 | 33,279.00 |
| Sep 30, 2025 | 33,279.00 |
| Jun 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 379,144.00 |
| Mar 31, 2025 | 379,144.00 |
| Dec 31, 2024 | 50,544.00 |
| Dec 31, 2024 | 50,544.00 |
| Sep 30, 2024 | 53,302.00 |
| Sep 30, 2024 | 53,302.00 |
| Jun 30, 2024 | 62,601.00 |
| Jun 30, 2024 | 62,601.00 |
| Mar 31, 2024 | 79,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Dec 31, 2023 | -581,731.00 |
| Dec 31, 2023 | -581,731.00 |